Bristol-Myers, Merck making bids for share of hepatitis C market
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb and Merck & Co are emerging as formidable competitors in the race for better hepatitis C treatments, a trend that will be apparent at an upcoming medical conference.